These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 36933756)

  • 1. Peptide-functionalized therapeutic nanoplatform for treatment orthotopic triple negative breast cancer and bone metastasis.
    Li D; Ma S; Xu D; Meng X; Lei N; Liu C; Zhao Y; Qi Y; Cheng Z; Wang F
    Nanomedicine; 2023 Jun; 50():102669. PubMed ID: 36933756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
    Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
    Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR-targeted multifunctional polymersomal doxorubicin induces selective and potent suppression of orthotopic human liver cancer in vivo.
    Fang Y; Yang W; Cheng L; Meng F; Zhang J; Zhong Z
    Acta Biomater; 2017 Dec; 64():323-333. PubMed ID: 29030307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuning Peptide-Based Nanofibers for Achieving Selective Doxorubicin Delivery in Triple-Negative Breast Cancer.
    Bellavita R; Piccolo M; Leone L; Ferraro MG; Dardano P; De Stefano L; Nastri F; Irace C; Falanga A; Galdiero S
    Int J Nanomedicine; 2024; 19():6057-6084. PubMed ID: 38911501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide mediated active targeting and intelligent particle size reduction-mediated enhanced penetrating of fabricated nanoparticles for triple-negative breast cancer treatment.
    Hu G; Chun X; Wang Y; He Q; Gao H
    Oncotarget; 2015 Dec; 6(38):41258-74. PubMed ID: 26517810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small Peptide Ligands for Targeting EGFR in Triple Negative Breast Cancer Cells.
    Hossein-Nejad-Ariani H; Althagafi E; Kaur K
    Sci Rep; 2019 Feb; 9(1):2723. PubMed ID: 30804365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sophoraflavanone G suppresses the progression of triple-negative breast cancer via the inactivation of EGFR-PI3K-AKT signaling.
    Cheng W; Liu D; Guo M; Li H; Wang Q
    Drug Dev Res; 2022 Aug; 83(5):1138-1151. PubMed ID: 35426453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of miR-361-5p in triple-negative breast cancer (TNBC) inhibits migration and invasion by targeting RQCD1 and inhibiting the EGFR/PI3K/Akt pathway.
    Han J; Yu J; Dai Y; Li J; Guo M; Song J; Zhou X
    Bosn J Basic Med Sci; 2019 Feb; 19(1):52-59. PubMed ID: 29924958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR-Targeted Liposomes Combined with Ginsenoside Rh2 Inhibit Triple-Negative Breast Cancer Growth and Metastasis.
    Gu H; Shi R; Xu C; Lv W; Hu X; Xu C; Pan Y; He X; Wu A; Li J
    Bioconjug Chem; 2023 Jun; 34(6):1157-1165. PubMed ID: 37235785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix Metalloproteinase-2-Responsive Surface-Changeable Liposomes Decorated by Multifunctional Peptides to Overcome the Drug Resistance of Triple-Negative Breast Cancer through Enhanced Targeting and Penetrability.
    Liu C; Zhao Z; Gao R; Zhang X; Sun Y; Wu J; Liu J; Chen C
    ACS Biomater Sci Eng; 2022 Jul; 8(7):2979-2994. PubMed ID: 35666956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GE11-antigen-loaded hepatitis B virus core antigen virus-like particles efficiently bind to TNBC tumor.
    Zhang L; Tang L; Jiang Y; Wang C; Huang L; Ding T; Zhang T; Li H; Xie L
    Front Oncol; 2023; 13():1110751. PubMed ID: 37020877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folic acid based carbon dot functionalized stearic acid-g-polyethyleneimine amphiphilic nanomicelle: Targeted drug delivery and imaging for triple negative breast cancer.
    Sarkar P; Ghosh S; Sarkar K
    Colloids Surf B Biointerfaces; 2021 Jan; 197():111382. PubMed ID: 33160259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases.
    Shin SU; Cho HM; Das R; Gil-Henn H; Ramakrishnan S; Al Bayati A; Carroll SF; Zhang Y; Sankar AP; Elledge C; Pimentel A; Blonska M; Rosenblatt JD
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CD44 and EGFR Dual-Targeted Solid Lipid Nanoparticles for Delivery of Doxorubicin to Triple-Negative Breast Cancer Cell Line: Preparation, Statistical Optimization, and
    Darabi F; Saidijam M; Nouri F; Mahjub R; Soleimani M
    Biomed Res Int; 2022; 2022():6253978. PubMed ID: 35845934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GE11-Directed Functional Polymersomal Doxorubicin as an Advanced Alternative to Clinical Liposomal Formulation for Ovarian Cancer Treatment.
    Zou Y; Xia Y; Meng F; Zhang J; Zhong Z
    Mol Pharm; 2018 Sep; 15(9):3664-3671. PubMed ID: 29570299
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Wan X; Sun R; Bao Y; Zhang C; Wu Y; Gong Y
    Mol Pharm; 2021 Nov; 18(11):3990-3998. PubMed ID: 34591491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
    Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
    Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ginsenoside 20(S)-protopanaxadiol inhibits triple-negative breast cancer metastasis in vivo by targeting EGFR-mediated MAPK pathway.
    Peng B; He R; Xu Q; Yang Y; Hu Q; Hou H; Liu X; Li J
    Pharmacol Res; 2019 Apr; 142():1-13. PubMed ID: 30735802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Cyclic Peptides Targeting the Epidermal Growth Factor Receptor in Mesenchymal Triple-Negative Breast Cancer Subtype.
    Nisticò N; Aloisio A; Lupia A; Zimbo AM; Mimmi S; Maisano D; Russo R; Marino F; Scalise M; Chiarella E; Mancuso T; Fiume G; Omodei D; Zannetti A; Salvatore G; Quinto I; Iaccino E
    Cells; 2023 Apr; 12(7):. PubMed ID: 37048151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.